{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:35:22Z","timestamp":1783110922662,"version":"3.54.6"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.lungcan.2015.02.012","type":"journal-article","created":{"date-parts":[[2015,2,23]],"date-time":"2015-02-23T20:00:28Z","timestamp":1424721628000},"page":"187-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib"],"prefix":"10.1016","volume":"88","author":[{"given":"Kuan-Li","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ju","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Jen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-An","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Yu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ju","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Hsiang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Yu","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Ying","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shah-Hwa","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-Chih","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inn-Wen","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Shyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2015.02.012_bib0205","series-title":"Cancer","author":"WHO. World Health Organization","year":"2014"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0210","series-title":"United States Cancer Statistics (USCS)","author":"US-CDC","year":"2014"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0215","series-title":"Cause of deaths statistics","author":"Ministry of Health and Welfare, Executive Yuan, Taiwan, R.O.C.","year":"2014"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/JTO.0b013e3181c5920c","article-title":"Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey","volume":"5","author":"Morgensztern","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0225","series-title":"Cancer Registry Annual Report, 2011, Taiwan","author":"Health Promotion Administration, Ministry of Health and Welfare","year":"2014"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0230","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0235","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0240","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"North-East Japan Study G. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0245","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jnci\/dji055","article-title":"Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers","volume":"97","author":"Shigematsu","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0250","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2007.15.6695","article-title":"Specific EGFR mutations predict treatment outcome of stage IIIB\/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy","volume":"26","author":"Yang","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0255","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00408-013-9482-4","article-title":"Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18\u201321 sequencing results of 753 patients and subsequent clinical outcomes","volume":"191","author":"Locatelli-Sanchez","year":"2013","journal-title":"Lung"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0260","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1136\/jclinpath-2011-200169","article-title":"Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations","volume":"64","author":"Won","year":"2011","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0265","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cllc.2012.10.007","article-title":"Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib","volume":"14","author":"Park","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0270","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.lungcan.2013.05.021","article-title":"Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations","volume":"81","author":"Ichihara","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0275","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.lungcan.2014.01.022","article-title":"Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations","volume":"84","author":"Kim","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0280","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/JTO.0b013e31828c3929","article-title":"Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation","volume":"8","author":"Tanaka","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0285","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/01243894-200607000-00004","article-title":"Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients","volume":"1","author":"Chang","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0290","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","article-title":"Metastatic sites and survival in lung cancer","volume":"86","author":"Riihimaki","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0295","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2013.08.012","article-title":"Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy","volume":"65","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0300","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0305","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10585-014-9648-3","article-title":"Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis","volume":"31","author":"Fujimoto","year":"2014","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0310","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/jjco\/hyd139","article-title":"Prognostic factors in advanced non-small cell lung cancer: elevated serum levels of neuron specific enolase indicate poor prognosis","volume":"30","author":"Maeda","year":"2000","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0315","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3892\/ol.2012.792","article-title":"Specific organ metastases and survival in small cell lung cancer","volume":"4","author":"Nakazawa","year":"2012","journal-title":"Oncol Lett"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0320","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2407-13-36","article-title":"Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer","volume":"13","author":"Riihimaki","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0325","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ijc.27988","article-title":"Site-specific survival rates for cancer of unknown primary according to location of metastases","volume":"133","author":"Hemminki","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0330","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/00498250400026464","article-title":"Cytochrome P450-dependent metabolism of gefitinib","volume":"35","author":"McKillop","year":"2005","journal-title":"Xenobiotica"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0335","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00280-011-1611-2","article-title":"The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib","volume":"68","author":"Horak","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0340","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1002\/ijc.26031","article-title":"The seed and soil hypothesis revisited: the role of tumor-stroma interactions in metastasis to different organs","volume":"128","author":"Langley","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0345","doi-asserted-by":"crossref","first-page":"351959","DOI":"10.1155\/2014\/351959","article-title":"Tumor microenvironment: a new treatment target for cancer","volume":"2014","author":"Tsai","year":"2014","journal-title":"ISRN Biochem"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0350","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4149\/neo_2014_021","article-title":"CD133 positive cells isolated from A549 cell line exhibited high liver metastatic potential","volume":"61","author":"Zhang","year":"2014","journal-title":"Neoplasma"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0355","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3892\/mco.2013.195","article-title":"Clinicopathological significance of CD133 in lung cancer: A meta-analysis","volume":"2","author":"Tan","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0360","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ni.2691","article-title":"Immune surveillance by the liver","volume":"14","author":"Jenne","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0365","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000357129","article-title":"Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer","volume":"86","author":"Fukihara","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0370","doi-asserted-by":"crossref","first-page":"e107161","DOI":"10.1371\/journal.pone.0107161","article-title":"Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0375","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"West Japan Oncology G. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0380","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","article-title":"Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)","volume":"29","author":"Fukuoka","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0385","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1158\/1078-0432.CCR-09-0391","article-title":"Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations","volume":"15","author":"Morita","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0390","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1378\/chest.10-3149","article-title":"Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment","volume":"141","author":"Chung","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0395","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.lungcan.2014.09.002","article-title":"Number of liver metastatic nodules affects treatment options for pulmonary adenocarcinoma patients with liver metastases","volume":"86","author":"Tseng","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2015.02.012_bib0400","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00280-012-1929-4","article-title":"Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer","volume":"70","author":"Togashi","year":"2012","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500215001191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500215001191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T01:18:38Z","timestamp":1566350318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500215001191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0169500215001191"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.02.012","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}